SEARCH

SEARCH BY CITATION

References

  • 1
    Felson DT, Anderson JJ, Meenan RF: Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum 33: 140149, 1990
  • 2
    Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 37: 393406, 1968
  • 3
    Van der Heijde DMFM, van 't Hof MA, van Riel PLCM, Theunisse LAM, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LBA: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49: 916920, 1990
  • 4
    Van Riel PLCM, van de Putte LBA: DC-ART: what proportion of response constitutes a positive response? J Rheumatol Suppl 21: 5456, 1994
  • 5
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, Tubwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727735, 1995
  • 6
    Furst DE: Considerations on measuring decreased inflammatory synovitis. ILAR Bull 2: 1721, 1994
  • 7
    Tugwell P, Bombardier C: A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 9: 758762, 1982
  • 8
    Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 9: 175176, 1958
  • 9
    Van 't Hof MA, Kowalski CJ: In, A Mixed Longitudinal Interdisciplinary Study of Growth and Development. Edited by B PrahlAnderson, CHKowalski, PHeyendaal. New York, Academic Press, 1979
  • 10
    Nuver-Zwart HH, van Riel PLCM, van de Putte LBA, Gribnau FWJ: A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis. Ann Rheum Dis 48: 389395, 1989
  • 11
    Van der Heijde DMFM, van Riel PLCM, Nuver-Zwart HH, Gribnau FWJ, van de Putte LBA: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1: 10361038, 1989
  • 12
    Van der Heijde DMFM, van Riel PLCM, van de Putte LBA: Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine and sulphasalazine. Scand J Rheumatol 19: 407412, 1990
  • 13
    Fries JF, Bloch DA, Sharp JT, McShane DJ, Spitz P, Bluhm GB, Forrester D, Genant H, Gofton P, Richman S, Weissman B, Wolfe F: Assessment of radiologic progression in rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 29: 19, 1986
  • 14
    Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Disease Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33: 477484, 1990
  • 15
    Davis MJ, Dawes PT: A disease activity index: its use in clinical trials and disease assessment in patients with rheumatoid arthritis. Semin Arthritis Rheum 23 (Suppl 1): 5056, 1993
  • 16
    Scott DL: A simple index to assess disease activity in rheumatoid arthritis. J Rheumatol 20: 582584, 1993
  • 17
    Kirwan JR: Outcome measures in rheumatoid arthritis clinical trials: assessing improvement. J Rheumatol 20: 543545, 1993
  • 18
    Dixon JS: Response criteria for slow acting antirheumatic drugs (letter). Ann Rheum Dis 49: 819820, 1990
  • 19
    Boers M: Low-dose prednisone in rheumatoid arthritis patients: placebo treatment? (Letter) Arthritis Rheum 34: 501502, 1991
  • 20
    Fuchs HA: The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol 20: 18631866, 1993
  • 21
    Anderson JJ: Sensitivity to change of rheumatoid arthritis clinical trial outcome measures. J Rheumatol 20: 535537, 1993
  • 22
    Dixon JS, Hayes S, Constable PDL, Bird HA: What are the “best” measurements for monitoring patients during short-term second-line therapy? Br J Rheumatol 27: 3743, 1988
  • 23
    Redelmeier DA, Lorig K: Assessing the clinical importance of symptomatic improvements. Arch Intern Med 153: 13371342, 1993
  • 24
    Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM: Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 4448, 1995